Abstract 1776P
Background
The global increase in obesity parallels the increase in PCa incidence, but the role of excess weight and weight change throughout adult life and their implications for PCa risk and prognosis are still under debate. We studied whether pre-diagnostic body mass index (BMI) and weight change is linked to PCa risk and prognosis.
Methods
A total of 16 879 healthy men were included to study PCa risk and prognosis in the Prostate Cancer Study throughout life (PROCA-life), based on those who participated in the prospective cohort Tromsø Study (1994-2016). Pre-diagnostic BMI and weight change (relative weight change in percent of baseline weight between two waves of the Tromsø study) during follow-up were measured. Detailed information from histopathological and clinical medical records for PCa cases were obtained. Cox proportional hazard and logistic regression models were used to estimate hazard ratios (HRs) and odds ratios (ORs) for the associations between pre-diagnostic measurements of BMI and weight change during follow-up, and PCa risk and overall and PCa specific mortality. Regression models were used to evaluate incidence rate ratios (IRR).
Results
Overall, the participants had a median age at study entry of 44 years, 46.0% were overweight and 13.8% were obese. In total 904 men developed PCa during follow-up, with a median age at diagnosis of 68 years. The incidence rates for PCa increased from 1995 to 2019 (overall IRR 2.27, 95% CI 1.82-2.83). We observed that men with a pre-diagnostic BMI ≥ 30kg/m2 at study entry, and who had a weight gain > 5% during follow-up, had a three-fold increased risk for incident PCa (HR 2.94, 95% CI 1.36-6.36). Overweight was associated with lower Gleason grade (OR 0.64, 95% CI 0.43-0.96) and lower Prostate Specific Antigen (OR 0.69, 95% CI 0.48-0.99). Overall, 311 PCa cases died, of whom 154 was PCa related deaths (17%). Pre-diagnostic obesity was associated with PCa-specific death (HR 1.73, 95% CI 1.03-2.91).
Conclusions
Our observation that weight gain in adult pre-diagnostic obese men was associated with increased risk for incident PCa, and that pre-diagnostic obesity increased the risk of PCa-mortality, support the importance to combat excess weight gain in the general population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Data protection office at University Hospital of North-Norway (UNN).
Funding
University of Tromsø.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1773P - ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era
Presenter: Wanling Xie
Session: Poster session 14
1774P - PC-PEP, a comprehensive daily six-month home-based prostate cancer: Patient empowerment program improves quality of life, physical fitness, and urinary function outcomes among prostate cancer patients with localized disease - Secondary analyses of a randomized clinical trial
Presenter: Gabriela Ilie
Session: Poster session 14
1775P - A newly-developed deep-learning algorithm: NAFNet outperforms ResNet50 for predicting adverse pathology events and biochemical recurrence time using MRI from prostate cancer patients
Presenter: Zheng Liu
Session: Poster session 14
1777P - Enzalutamide (enza) monotherapy for the treatment (tx) of prostate cancer with high-risk biochemical recurrence (BCR): EMBARK secondary endpoints
Presenter: Ugo De Giorgi
Session: Poster session 14
1778P - Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK
Presenter: Stephen Freedland
Session: Poster session 14
1779P - PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial
Presenter: Giulio Francolini
Session: Poster session 14
1780P - The health inequality impact of darolutamide for non-metastatic castration-resistant prostate cancer: A distributional cost-effectiveness analysis
Presenter: Jeroen Jansen
Session: Poster session 14
1782P - Prostate radiotherapy reduces long-term risk of obstructive uropathy in metastatic hormone sensitive prostate cancer (mHSPC): Results from the STAMPEDE M1|RT comparison
Presenter: Craig Jones
Session: Poster session 14
1783P - PROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Efficacy results from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14